AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05004233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection after antiplatelet treatment
Description: A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit
Study NCT06282289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Magnetoencephalography (MEG)
Description: Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.
Study NCT06282289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognition development questionnaire
Description: Computerised questionnaires completed by parents
Study NCT05119725 — intervention group
Intervention type: DEVICE
Intervention: continous 3 day EKG monitoring with S-Patch Cardio
Description: continous 3 day EKG monitoring with S-Patch Cardio
Study NCT05108467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care Lactate
Description: StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods.
Study NCT05351892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Soft gel capsule, oral
Study NCT04260217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 400 mg
Description: APG2575 400 mg
Study NCT04260217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 600 mg
Description: APG2575 600 mg
Study NCT04260217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 800 mg
Description: APG2575 800 mg
Study NCT05747651 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Total volume of blood (on each sampling occasion): 54,5mL.
Study NCT05747651 — intervention group
Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted.
Study NCT05747651 — intervention group
Intervention type: BIOLOGICAL
Intervention: Saliva sample
Description: Saliva: will be collected in special container for saliva microbiome and methylation.
Study NCT05747651 — intervention group
Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C.
Study NCT05747651 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tissue sample
Description: Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.
Study NCT06492850 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-002
Description: Intraocular injection of a single dose
Study NCT06359522 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS monitor
Description: NIRS monitoring data will be collected to determine organ perfusion.
Study NCT04922528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy with Fluorescent Cholangiography
Description: Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
Study NCT04922528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy with White Light Imaging
Description: As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
Study NCT04922528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy with White Light Imaging
Description: As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
Study NCT05341245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graphene oxide and open flap debridement
Description: Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
Study NCT05341245 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open flap debridement
Description: Using Open flap debridement in management of periodontal intrabony defects in dogs
Study NCT04380051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensory-tonic stimulation
Description: sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
Study NCT04380051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: skin-to-skin contact left free for parents
Study NCT04380051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: skin-to-skin contact
Description: skin-to-skin contact left free for parents
Study NCT05728944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: Aceclidine + Brimonidine combination ophthalmic solution
Study NCT05728944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine
Description: Aceclidine ophthalmic solution
Study NCT05728944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Proprietary vehicle ophthalmic solution
Study NCT06393400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant
Study NCT06393400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG3350
Description: Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX
Study NCT06393400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Gemzar
Study NCT06393400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Abraxane
Study NCT05206877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, 4 units
Description: Topical insulin 100 U/ml, 1 drop per day
Study NCT05206877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, 20 units
Description: Topical insulin 500 U/ml, 1 drop per day
Study NCT05206877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 4 units twice daily
Description: 1 drop of low dose insulin twice daily.
Study NCT05206877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 20 units twice daily
Description: 1 drop of high dose insulin twice daily
Study NCT05206877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 4 units three times daily
Description: 1 drop of low dose insulin three times daily.
Study NCT05206877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin, 20 units three times daily
Description: 1 drop of high dose insulin three times daily.
Study NCT05219565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attractive Targeted Sugar Bait (ATSB)
Description: An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
Study NCT05631028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
Study NCT05631028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
Study NCT04770103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance recovery
Description: Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability.
Study NCT04770103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural Sway
Description: Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability.
Study NCT06060301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine 500 MG
Description: The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
Study NCT06060301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: The patients will use topical corticosteroids 4 times per day.
Study NCT06060301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: The patients will use topical corticosteroids 4 times per day.
Study NCT04847128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic aerobic exercise
Description: Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
Study NCT06216561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-HIPEC + LSTA1
Description: LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)
Study NCT06216561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRS-HIPEC alone
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
Study NCT06559514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based multi-component psychoeducational inventions (GMC-PEIs)
Description: The participants were randomly assigned to either the experimental group, using a computer-generated list of random numbers.
Study NCT06380816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4594
Description: Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
Study NCT04870606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proxalutamide (GT0918)
Description: Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
Study NCT04870606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo+Standard of care determined by PI and local regulatory
Study NCT05867017 — intervention group
Intervention type: OTHER
Intervention: Measure of physiologic parameters
Description: Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Study NCT05642286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLVAS® robotic-assisted PCI
Description: ALLVAS® robotic-assisted PCI
Study NCT05323916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroproprioceptive facilitation, inhibition
Description: Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy.
Study NCT05323916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology based physical therapy
Description: Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
Study NCT05323916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectively managed rehabilitation implementing the recommendations of the World Health Organization
Description: Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
Study NCT05323916 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
Study NCT06562738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
Study NCT04917328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression ultrasound
Description: performing a compression ultrasound
Study NCT04989491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: One single dose of rituximab intravenously (IV)
Study NCT04989491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: No treatment
Study NCT06091501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lev Livet
Description: The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention.
Study NCT05015023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: A cluster-randomized controlled trial will be conducted.
Study NCT04705571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MorpheusV Applicator
Description: 1 treatment with the MorpheusV Applicator
Study NCT05188794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral tap block
Description: In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
Study NCT05188794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior tap block
Description: In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
Study NCT05374343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1
Study NCT05374343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1
Study NCT06125990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Study Group (SGr)
Description: For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
Study NCT06125990 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control Group (CGr)
Description: Only institutional conventional rehabilitation was implemented.
Study NCT06418815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept map group
Description: The intervention group will create a concept map regarding neonatal toxic stress.
Study NCT05009420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado
Description: avocado served with crackers as breakfast
Study NCT04034615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells low-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
Study NCT06064994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: The experimental group received the Smith's version of the mindfulness meditation (Smith, 2005), which is a standardized theory-based intervention found to be effective in improving the different dimensions of health. The Smith's version of the mindfulness meditation (Smith, 2005), includes the following components:~1. Being mindful of breathing (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of thought (5 minutes).~4. Being mindful of sounds (5 minutes).~5. Being mindful of taste (5 minutes)~6. Full meditation
Study NCT05408221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rulonilimab+Lenvatinib
Description: Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
Study NCT05408221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rulonilimab placebo +Lenvatinib
Description: Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
Study NCT05363800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-3738
Description: HRS-3738 will be administrated per dose level in which the patients are assigned.
Study NCT04502524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention (New website)
Description: Complete the new website smoking cessation program
Study NCT04502524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention (Standard of care website)
Description: Complete the standard of care website smoking cessation intervention
Study NCT04502524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
Study NCT04502524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
Study NCT04502524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive motivational and reminder text messages